Mutation Profiling of Usual Ductal Hyperplasia of the Breast Reveals Activating Mutations Predominantly at Different Levels of the PI3K/AKT/mTOR Pathway  by Jahn, Stephan W. et al.
The American Journal of Pathology, Vol. 186, No. 1, January 2016ajp.amjpathol.orgSHORT COMMUNICATION
Mutation Proﬁling of Usual Ductal Hyperplasia
of the Breast Reveals Activating Mutations
Predominantly at Different Levels of the PI3K/AKT/mTOR
Pathway
Stephan W. Jahn,* Karl Kashofer,* Andrea Thüringer,* Luca Abete,* Elke Winter,* Sylvia Eidenhammer,* Christian Viertler,*
Fattaneh Tavassoli,y and Farid Moinfar*z
From the Institute of Pathology,* Medical University of Graz, Graz, Austria; the Department of Pathology,y Yale University School of Medicine, New Haven,
Connecticut; and the Department of Pathology,z Hospital of the Sisters of Charity, Linz, AustriaAccepted for publication
September 28, 2015.
Address correspondence to
Stephan W. Jahn, M.D.,
Institute of Pathology, Medical
University of Graz,
Auenbruggerplatz 25, 8036
Graz, Austria. E-mail: stephan.
jahn@medunigraz.at.
Copyright ª 2016 American Society for Inv
This is an open access article under the CC
http://dx.doi.org/10.1016/j.ajpath.2015.09.00Usual ductal hyperplasia (UDH) of the breast is generally regarded as a nonneoplastic proliferation,
albeit loss of heterozygosity has long been reported in a part of these lesions. To gain deeper insights
into the molecular drivers of these lesions, an extended mutation proﬁling was performed. The coding
regions of 409 cancer-related genes were investigated by next-generation sequencing in 16 cases of
UDH, nine unassociated with neoplasia (classic) and seven arising within papillomas. Phosphatidyli-
nositol 3-kinase/AKT/mammalian target of rapamycin (mTOR) activation was investigated by phos-
phorylated AKT, mTOR, and S6 immunohistochemistry. Of 16 lesions, 10 (63%) were mutated; 56% of
classic lesions were unassociated with neoplasia, and 71% of lesions arose in papillomas. Fourteen
missense mutations were detected: PIK3CA [6 (43%) of 14], AKT1 [2 (14%) of 14], as well as GNAS,
MTOR, PIK3R1, LPHN3, LRP1B, and IGF2R [each 1 (7%) of 14]. Phosphorylated mTOR was seen in 83%
and phosphorylated S6 in 86% of evaluable lesions (phospho-AKT staining was technically uninter-
pretable). In conclusion, UDH displays mutations of the phosphatidylinositol 3-kinase/AKT/mTOR axis
at different levels, with PIK3R1, MTOR, and GNAS mutations not previously described. Speciﬁcally,
oncogenic G-protein activation represents a yet unrecognized route to proliferation in UDH. On the
basis of evidence of activating mutations, loss of heterozygosity, and a mass forming proliferation, we
propose that UDH is most appropriately viewed as an early neoplastic intraductal proliferation.
(Am J Pathol 2016, 186: 15e23; http://dx.doi.org/10.1016/j.ajpath.2015.09.004)Supported by the Institute of Pathology, Medical University of Graz,
internal funds designated for research purposes.
Disclosures: None declared.Usual ductal hyperplasia (UDH)of thebreast ismorphologically
characterized by a heterogeneous intraductal proliferation of
mammary duct epithelial cells characteristically admixed with
modiﬁed myoepithelial cells. Although atypical ductal hyper-
plasia (ADH) and low-grade ductal carcinoma in situ (DCIS)
form a morphological continuum of intraductal neoplastic pro-
liferations (ductal intraepithelial neoplasias) delineated in
routine diagnostic pathology by arbitrary morphological
(quantitative) criteria,1,2 UDH is currently denoted as a non-
neoplastic epithelial proliferation in daily practice. It has long
been recognized that proliferative breast lesions without atypia,
such as UDH, radial scars, and complex sclerosing lesions, are
associated with a mildly elevated risk for the development ofestigative Pathology. Published by Elsevier In
BY-NC-ND license (http://creativecommons.o
4invasive breast cancer3,4; nevertheless, genetic data onUDHand
its link to invasive cancer are still sparse.Theneoplastic natureof
UDHwas initially suggested on the basis of the detection of loss
of heterozygosity in some of these lesions5e10 and divergent
reports on the presence ofESR1mutations.11,12 Recentmutation
analyses have demonstrated activating mutations in the phos-
phatidylinositol-3-kinase pathway in so-called columnar cell
lesions of the mammary duct epithelium, in a subset of UDH
and within radial scars.13e15c.
rg/licenses/by-nc-nd/4.0).
Jahn et alThe aim of this study was to evaluate UDH of the breast
for the presence of somatic mutations to gain insight into the
alterations driving their neoplastic growth and to use so-
matic mutation status as evidence for a possible neoplastic
nature of these lesions. We therefore investigated UDH
unassociated with currently acknowledged neoplastic alter-
ations (ie, intraductal papilloma, ﬂat epithelial atypia, ADH,
DCIS, and lobular intraepithelial neoplasia encompassing
atypical lobular hyperplasia and lobular carcinoma in situ)
and invasive breast cancer. In addition, UDH in intraductal
papillomas in patients devoid of other neoplastic alterations,
as cited above, was investigated, with the exception of one
patient with a concomitant syringomatous adenoma in other
areas of the specimen not used for analysis. UDH was
analyzed for mutations in the coding regions of 409 cancer-
related genes (oncogenes and tumor-suppressor genes) by
next-generation sequencing. To assess activation of the
phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian
target of rapamycin (mTOR) signaling cascade, which
constitutes the most important pathway active in mammary
epithelial neoplasias, we performed immunohistochemistry
for AKT phosphorylated at Serin 473 (p-AKT), mTOR
phosphorylated at Serin 2448 (p-mTOR), and ribosomal
protein S6 phosphorylated at Serin 240 (p-S6) as a down-
stream target of mTOR.Table 1 Clinicopathological Characteristics of Investigated Lesions a
Case Gene symbol Mutation
Assessed
biological
relevance*
UDHs arising in papillomas
1 AKT1 p.E17K Yes
GNAS p.R201H
p.R844Hy
Yes
2 IGF2R p.V1888L No
3 AKT1 p.E17K Yes
MTOR p.V2406M Yes
4 PIK3CA p.H1047R Yes
5 None
6 None
7 PIK3CA p.H1047R Yes
LPHN3 p.R465Q No
UDHs unassociated with papilloma
8 PIK3CA p.E542K Yes
9 PIK3CA p.E545K Yes
LRP1B p.R3323H No
10 PIK3CA p.H1047R Yes
11 None
12 PIK3CA p.H1047R Yes
13 PIK3R1 p.K567E, p.K267E,y p.K297Ey Yes
14 None
15 None
16 None
*On the basis of evaluation of Sorting Intolerant From Tolerant algorithm sc
yAlternative annotation of mutation at identical genomic location in the Cos
zMaximum diameter of multiple adjacent foci.
Max, maximum; UDH, usual ductal hyperplasia.
16Materials and Methods
Sample Selection
Approval from the ethics committee of the Medical Uni-
versity of Graz (Graz, Austria) and the Institutional Review
Board of the Yale University School of Medicine (New
Haven, CT) was obtained for the study. Case selection was
on the basis of evaluation of computerized pathological
reports from the Institute of Pathology (Medical University
of Graz) screened for surgical specimens comprising UDH
in sufﬁcient quantity to allow for analysis and then assigned
to one of the two groups. The ﬁrst group comprised 10 cases
of UDH unassociated with any currently acknowledged
neoplastic alterations (including papilloma, DCIS, and
invasive breast cancer). Only lesions from patients without a
history of any such lesions in the medical records available
to us were selected. The second group consisted of seven
cases of UDH within intraductal papilloma and the patient’s
medical history equally devoid of other neoplastic alter-
ations up to the time of resection, with the exception of one
case (papilloma with UDH, Case 6) (Table 1) with a
concomitant syringomatous adenoma in other areas of the
specimen not used for analysis. Slides and formalin-ﬁxed,
parafﬁn-embedded (FFPE) tissue were provided by thend Mutations Detected
Size of
lesion,
UDH, cm
Patient
age, years
Apocrine
metaplasia
Size of apocrine
metaplastic focus, cm
1.0 53 Yes 0.5
0.8 61 Yes 0.1
0.7 56 Yes Multiple foci (<0.15)
1.4 40 No
0.4 39 Yes Two foci (<0.08)
0.7 63 No
0.9 74 No
Max, 0.2z 73 No
Max, 0.2z 48 No
0.5 59 No
0.5 37 No
Max, 0.4z 23 No
0.3 35 Yes Single focus (0.15)
0.4 71 No
0.3 51 No
0.3 48 No
ore and literature/database search.
mic database.
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Mutations in Usual Ductal HyperplasiaBiobank of the Medical University of Graz (Graz, Austria)
in 16 cases. In one case, tissue was provided externally by
the Department of Pathology, Yale Medical School. All
cases were reviewed by two pathologists (F.M. and S.W.J.),
and modiﬁed, myoepithelial cells were veriﬁed by positive
immunoreaction for keratin 14. The mean patient age was
49 years for patients with UDH unassociated with neoplasia/
papilloma and 55 years for UDH arising in papilloma.
Mutation Analysis by Next-Generation Sequencing
Unstained, parafﬁnized serial sections with corresponding
hematoxylin and eosinestained levels for topographic
reference were obtained. FFPE tissue from lesions (UDH
and UDH arising in papilloma) and corresponding normal
breast tissue were manually microdissected from unstained
sections. The corresponding normal (nonlesional) reference
tissue was retrieved from either a different surgical spec-
imen of the same patient (preferred) or nonneoplastic tissue
of the same resection specimen, in case further material was
not available. In the one case provided externally, already
mounted slides were provided for histological assessment,
immunohistochemistry, and DNA retrieval. DNA was pu-
riﬁed on a Maxwell, MDxResearch System (Promega,
Fitchburg, WI). Highly multiplexed PCR was used to
generate amplicon libraries covering the coding region of
409 genes encompassing >50% of the Wellcome Trust
Sanger Institute Cancer Gene Census using the Compre-
hensive Cancer Panel primer pool (model 4477685; Thermo
Fisher Scientiﬁc, Waltham, MA). The complete gene list is
provided in Supplemental Table S1. Libraries were prepared
using the Ion AmpliSeq Library Kit 2.0 (model 4475345;
Thermo Fisher Scientiﬁc). Library preparation from UDH
was performed in duplicate, whereas a single library was
prepared from corresponding normal tissue. Sequencing was
performed on an Ion Proton Sequencer (Thermo Fisher
Scientiﬁc). Emulsion PCR and sequencing runs were per-
formed with the appropriate kits (Ion One Touch Template
Kit version 2 and Ion Proton 200 Sequencing Kit; Thermo
Fisher Scientiﬁc) using Ion PI chips. Sequencing length was
set to 520 ﬂows and yielded reads ranging from 70 to 150 bp,
consistent with the expected size range. On average, 20 million
reads were obtained for each DNA library with consistently
>80% of bases at Phred scaled quality following alignment 20.
Data Analysis
Initial data analysis was performed using the Ion Torrent
Suite Software version 4.1 Plug-ins (Thermo Fisher Scienti-
ﬁc, open source, general public license). Brieﬂy, this included
base calling, alignment to the reference genome (HG19)
using the Torrent Mapper and variant calling by a modiﬁed
diBayes approach by taking into account the ﬂow space in-
formation. All called variants were annotated using open
source software (Annovar,16 http://www.openbioinformatics.
org/annovar/annovar_download_form.php, and SnpEff,17The American Journal of Pathology - ajp.amjpathol.orghttp://snpeff.sourceforge.net/download.html; both last
accessed September 28, 2015) and custom Perl scripts
(available from the author upon request). Only coding,
nonsynonymous mutation calls present in both duplicates
from UDH and absent in nonlesional DNA were further
evaluated and visually inspected in Integrative Genomics
Viewer.18 Variant calls resulting from technical read errors or
sequence effects were excluded from the analysis. Mutations
were subsequently assessed for biological relevance by
computerized prediction (in silico prediction). Sorting
Intolerant From Tolerant algorithm (SIFT)19 was used to
generate SIFT scores. Mutations with scores <0.05 were
interpreted as functionally relevant (prediction damaging),
scores between 0.05 and 0.1 were regarded as possibly rele-
vant (possibly damaging), and scores>0.1 were regarded as
irrelevant (functionally neutral) by computerized pre-
diction. Final assessment of biological relevance was
interpreted in conjunction with data from the Cosmic
database20 and literature search, as explained in the text.
SPSS Statistics version 22 (IBM, New York, NY) was
used for statistical comparison of mutation frequencies
between classic UDH unassociated with neoplasia and
UDH arising in papillomas using Fisher’s exact test.
Immunohistochemistry for p-AKT, p-mTOR, and p-S6
FFPE sections (3 mm thick) were deparafﬁnized and stained
for Ser-473 phospho-AKT [clone D9E; Cell Signaling
Technology (CST), Danvers, MA], Ser-2448 phospho-
mTOR (clone 49F9; CST), and Ser-240 phospho-S6 (clone
DAK-S6-240; Dako, Glostrup, Denmark). Phospho-AKT
immunohistochemistry was performed with Tris (pH 9) heat
retrieval (microwave), and Dako þ diaminobenzidine
(DAB) was used as chromogen for visualization. Brieﬂy,
heat-mediated antigen retrieval (Tris, pH 9, buffer, micro-
wave), followed by primary antibody blocking for 1 hour
with 1 Tris-buffered saline Tween 20 plus 5% added
normal goat serum (model 5425; CST) and overnight in-
cubation (antibody diluted 1:25 in SignalStain antibody
diluent; CST) at 4C, followed by detection with Signal-
Stain Boost IHC Detection Reagent (horseradish peroxi-
dase, rabbit; CST). Subsequently, DAB (Envision DABþ;
Dako) was used as a chromogen for visualization. Slides
were counterstained with Mayer’s hemalum, dehydrated,
cleared, and coverslipped. For phospho-mTOR antigen,
retrieval with Tris, pH 9.0 (microwave), was performed,
followed by primary antibody incubation at a 1:100 dilution
for 45 minutes and visualization with Dako Envision
detection system, DAB (Chemmate; Dako) as chromogen,
and slides were counterstained and coverslipped as stated
above. For phospho-S6 immunohistochemistry, automated
staining on the BenchMark ULTRA stainer (Ventana
Medical Systems, Tucson, AZ) was used. Antigen retrieval
(cell conditioning solution 1; Ventana Medical Systems)
was used, and primary antibody was diluted 1:50 in anti-
body diluent (Ventana Medical Systems) and incubated for17
Jahn et al32 minutes. The ultraView universal DAB detection kit
(Ventana Medical Systems) was used as a secondary
detection system. For the purpose of this study, any staining
in epithelial cells of investigated lesions was scored as
positive.
Results
Seventeen patients were included in the study. Sixteen cases
were successfully analyzed, whereas in one case (UDH
unassociated with papilloma), insufﬁcient DNA quantity
necessitated exclusion of the patient from further analysis.18UDH was manually microdissected and mutation proﬁled
by next-generation sequencing. Both UDH unassociated
with currently acknowledged neoplastic alterations and
UDH arising in papillomas were investigated. In one case
(Case 1, papilloma with UDH), original levels evaluated
were devoid of areas suspicious for ADH, yet on keratin 14
immunohistochemistry, 2-minute foci of ADH (1.5 and <1
mm) appeared on deeper levels of the block used for tissue
harvesting and DNA preparation. Because these areas only
consisted of a small part of the entire lesion (whole lesion
diameter, 10 mm), the case was included in the study, and
focal transition to ADH was noted. Figure 1, AeD, depicts
exemplary cases with UDH-exhibiting mutations. Table 1Figure 1 A and B: Usual ductal hyperplasia
(UDH) arising in papilloma exhibiting PIK3CA
p.H1047R mutation (Case 4 of Tables 1 and 2; A)
and intermixed, modiﬁed myoepithelial cells
highlighted by K14 immunohistochemistry (B). C:
UDH with PIK3R1 p.K567E mutation (Case 13) and
associated apocrine metaplasia. D: Higher magni-
ﬁcation of boxed area in C. EeH: Immunohisto-
chemical p-mammalian target of rapamycin (mTOR;
E) and p-S6 (F) positivity in UDH arising in papil-
loma (Case 4), as well as p-mTOR (G) and p-S6 (H)
positivity in UDH unassociated with neoplasia (Case
12, PIK3CA p.H1047R). Original magniﬁcations:
10 (A, B, and DeF); 4 (C); 20 (G and H).
ajp.amjpathol.org - The American Journal of Pathology
Table 2 Mutation Details
Case Gene symbol Mutation Transcript
Genomic coordinate of
nucleotide alteration
% mutated
reads*
SIFT
score
UDHs arising in papilloma
1 AKT1 p.E17K NM_001014432.1 Chr 14: g. 105246551 C>T 58 0.01
GNAS p.R201H NM_000516.4 Chr 20: g. 57484421 G>A 44 0
2 IGF2R p.V1888L NM_000876.2 Chr 6: g.160500795 G>T 32 0.73
3 AKT1 p.E17K NM_001014432.1 Chr 14: g.105246551 C>T 43 0.01
MTOR p.V2406M NM_004958.3 Chr 1: g. 11174459 C>T 19 0.02
4 PIK3CA p.H1047R NM_006218.2 Chr 3: g.178952085 A>G 26 0.06
5 None
6 None
7 PIK3CA p.H1047R NM_006218.2 Chr 3: g. 178952085 A>G 42 0.06
LPHN3 p.R465Q NM_015236.4 Chr 4: g. 62758491 G>A 45 0.28
UDHs unassociated with papilloma
8 PIK3CA p.E542K NM_006218.2 Chr 3: g. 178936082 G>A 11 0.04
9 PIK3CA p.E545K NM_006218.2 Chr 3: g. 178936091 G>A 11 0
LRP1B p.R3323H NM_018557.2 Chr 2: g. 141208226 C>T 20 0.13
10 PIK3CA p.H1047R NM_006218.2 Chr 3: g. 178952085 A>G 39 0.06
11 None
12 PIK3CA p.H1047R NM_006218.2 Chr 3: g. 178952085 A>G 12 0.06
13 PIK3R1 p.K567E NM_181523.2 Chr 5: g. 67591106 A>G 23 0
14 None
15 None
16 None
*Represent mean of duplicate analyses.
Chr, chromosome; SIFT, Sorting Intolerant From Tolerant algorithm; UDH, usual ductal hyperplasia.
Mutations in Usual Ductal Hyperplasiagives an overview of mutations detected, an assessment of
their biological relevance predicted by SIFT score in
conjunction with information from the Cosmic database and
literature search, size of UDH, as determined by histological
measurement, patient age, and the extent of any concomitant
apocrine metaplasia. Table 2 summarizes mutation details
[gene symbol protein change (Human Genome Variation
Society nomenclature), reference transcript, genomic posi-
tion and nucleotide change, percentage mutated reads given
as mean value of technical duplicates, and SIFT score]. All
mutations detected were missense point mutations. Muta-
tions were detected in 5 (71%) of 7 UDHs within papilloma
and in 5 (56%) of 9 UDHs unassociated with neoplastic
alterations (difference not statistically signiﬁcant, PZ 0.6).
The mean diameter of mutated lesions (UDH) within pap-
illoma was 10 mm, and the mean diameter of UDH mutated
and unassociated with papilloma was 3 mm. The mean
percentage of mutated reads was 19% (range, 11% to 39%)
for UDH unassociated with neoplasia, compared with 39%
(range, 19% to 58%) for UDH arising in papilloma.
After the biological relevance of mutations was assessed
by computation of SIFT scores and evaluation of data from
the Cosmic database, 5 (56%) of 9 UDHs unassociated with
neoplasia and 4 (57%) of 7 UDHs arising in papillomas
exhibited missense mutations of presumed biological rele-
vance, consisting of AKT1, GNAS, MTOR, PIK3CA, and
PIK3R1 mutations. In UDHs unassociated with neoplasia,
four PIK3CA mutations and one PIK3R1 mutation were
found. In one of these PIK3CA mutated lesions, anThe American Journal of Pathology - ajp.amjpathol.orgadditional mutation in the LRP1B gene (p.R3323H) was
detected (SIFT score, 0.13; no Cosmic database entry),
which we regard as a functionally neutral (biologically
irrelevant) passenger mutation. Two cases of UDH arising
in papilloma demonstrated presumed passenger mutations,
with both mutations assessed as functionally neutral by
algorithmic prediction with SIFT: one case demonstrated a
mutation in the IGF2R gene (SIFT score, 0.73; single
Cosmic database entry), and a second case harbored a
LPHN3 mutation (SIFT score, 0.28; two Cosmic database
entries) in addition to a PIK3CA mutation. Among UDHs
arising in papillomas, two lesions showed a double mutation
(AKT1 and GNAS as well as AKT1 and MTOR). Overall
somatic mutations were conﬁrmed in 63% (10 of 16) of
UDHs investigated.
Immunohistochemical staining for p-AKT was unsuc-
cessful for technical reasons. Although designated positive
and negative controls [SignalSlide Phospho-Akt (Ser473)
IHC Controls 8101 purchased from CST] yielded strong
speciﬁc staining in parafﬁn-embedded LNCaP cells and
acceptable background in PI3K inhibitor LY294002-treated
LNCaP cells, positive controls of FFPE surgical tissue from
our own archived material with known PIK3CA mutations
and/or PTEN mutations and from samples of this study
yielded signal at approximately background level only, a
limitation not to be overcome by diverse antigen retrieval
conditions and antibody dilutions. We thus had to exclude
p-AKT immunohistochemistry from further evaluation
because of insufﬁcient sensitivity in our FFPE material.19
Table 3 Immunohistochemistry for Phosphorylated mTOR and
Phosphorylated S6 Protein
Case Gene symbol Mutation p-mTOR p-S6
UDHs arising in papilloma
1 AKT1 p.E17K þ 
GNAS p.R201H
2 IGF2R p.V1888L þ NE
3 AKT1 p.E17K þ þ
MTOR p.V2406M
4 PIK3CA p.H1047R þ þ
5 None þ þ
6 None þ þ
7 PIK3CA p.H1047R þ þ
LPHN3 p.R465Q
UDHs unassociated with papilloma
8 PIK3CA p.E542K þ þ
9 PIK3CA p.E545K NL NL
LRP1B p.R3323H
10 PIK3CA p.H1047R NE 
11 None NE þ
12 PIK3CA p.H1047R þ þ
13 PIK3R1 p.K567E  þ
14 None  þ
15 None NE þ
16 None þ þ
þ, positive; , negative; NE, not evaluable because staining unsuc-
cessful (negative internal positive control); NL, no lesion (lesional tissue
exhausted); p-mTOR, phospho-mammalian target of rapamycin; UDH, usual
ductal hyperplasia.
Jahn et alp-mTOR and p-S6, on the other hand, were evaluable in
most cases. Table 3 gives an overview of p-mTOR and p-S6
staining results, and Figure 1 illustrates p-mTOR and pS6
stains in UDHs arising in papilloma (Figure 1, E and F)
compared with staining in UDHs unassociated with papil-
loma (Figure 1, G and H). Unevaluable cases consisted of
one UDH unassociated with papilloma where deeper levels
were exhausted for lesional tissue and of four stains, which
were not evaluable for technical reasons (negative internal
positive control). Overall, 10 of 12 evaluable UDHs
demonstrated positivity for p-mTOR, and 12 of 14 evalu-
able lesions were positive for p-S6.
Discussion
UDH has mostly been viewed as a nonneoplastic prolifera-
tion of the mammary duct epithelium, a notion still regarded
as standard in terms of routine reporting. Evidence for a
clonal, neoplastic nature of UDH was originally derived
from loss of heterozygosity observed in 30% to 40% of
lesions.7,21e23 Additional evidence supporting the neoplastic
nature of UDH has recently emerged through the detection
of PIK3CA mutations in UDH, radial scars, and so-called
columnar cell lesions in cases largely associated with
concomitant DCIS and/or invasive breast cancer, depending
on the study.13e15,24,25 In contrast, we have analyzed UDH in
patients devoid of in situ or invasive breast cancer and one20case associated with a syringomatous adenoma (in a different
area of the specimen, Case 6), in which the investigated
lesion (UDH) displayed a wild-type status on molecular
analysis. Furthermore, only the hot spots of a comparably
restricted number of oncogenes were investigated in the
earlier mentioned studies, whereas our analysis comprised
the coding sequence of>400 cancer-related genes, including
almost all cardinal tumor-suppressor genes in breast cancer
(TP53, PTEN, RB1, ARID1A, NF1, and ATM).
Missense mutations were conﬁrmed in >60% of lesions
investigated. The proportion of lesions exhibiting mutations
was higher in UDHs arising in papillomas (71%) than in
classic UDHs not arising in papillomas (56%). Mutations in
PIK3CA, the most common oncogene in invasive breast
cancer and DCIS,26 were also most frequently seen in our
study. Of the 10 UDHs exhibiting mutations, 6 displayed
alterations in the PIK3CA gene (two exon 9 and four exon
20 mutations). PI3KCA is one of four catalytic subunits
(catalytic subunit a, b, g, or D), to be joined with one of ﬁve
regulatory subunits (PI3K-regulatory subunit a, b, g, 5, 6)
to constitute the heterodimeric PI3K class I complex.
Interestingly, apart from PI3K activation through mutation
of the catalytic subunit a, PI3K activation was achieved in
one case (UDHs unassociated with papilloma) through
alteration of the PI3K-regulatory subunit a, by mutation of
the encoding PIK3R1 gene (p.K567E). This pathogenic
mutation has been reported in esophageal carcinoma,27
Burkitt lymphoma,28 and endometrial carcinoma. The
amino acid alteration localizes to the iSH2 domain of PI3K-
regulatory subunit a and has been shown to uncouple and
retain its PI3KCA stabilizing activity, while abrogating its
inhibitory activity on PI3KCA.29 Mutations in PIK3R1,
other than the p.K567E mutation seen in our study, have
been described in a small proportion (2%) of invasive breast
cancers, according to the Cosmic database, but PIK3R1
mutations have not been previously reported in UDH or
carcinoma in situ. Mechanistically, PI3K activation (either
by mutated PIK3CA or PIK3R1) ﬁts well with reports on
oncogenic PI3K in DCIS as an early event in neoplastic
transformation of the mammary duct epithelium.30 In
agreement with our ﬁndings, Ang et al13 have recently re-
ported a similar PIK3CA mutation spectrum in proliferative
breast lesions without atypia, including 6 of 12 cases of
UDH displaying the p.E542K, p.E545K, and p.H1047R
mutation in PIK3CA.
Two cases of UDH arising in papilloma exhibited a well-
characterized AKT1 mutation (p.E17K). No AKT1 mutations
were described in UDH unassociated with papilloma in the
study of Ang et al13 either, but Troxell et al31 have identiﬁed
this AKT1 mutation in intraductal papillomas, including
cases with superimposed UDH. We observed AKT1 muta-
tions to be mutually exclusive, with oncogenic PI3K acti-
vation an inverse correlation also seen in invasive and
preinvasive breast cancer.26,30,32 Generally, the percentage
of AKT1-positive lesions in our study (13% for all lesions
compared with 30% for UDHs arising in papilloma) is muchajp.amjpathol.org - The American Journal of Pathology
Mutations in Usual Ductal Hyperplasiahigher than observed in invasive breast cancer, which dis-
plays AKT1 mutations in only 1.4%33 and 2% (Cosmic
database) of cases, indicating a low risk for malignant
transformation in AKT1 mutated breast lesions. Interest-
ingly, we found both AKT1 mutated cases to be associated
with a second oncogenic mutation, namely a GNAS muta-
tion in Case 1 and an MTOR mutation in Case 3. The lesion
with a combined AKT1 and GNAS mutation revealed small
foci of UDH with focal transition to ADH, whereas the
second case with a compound MTOR mutation did not.
GNAS mutations have repeatedly been found together with a
second KRAS mutation in gastrointestinal tract tumors,34,35
an analogous observation to the AKT1 and GNAS com-
pound mutation in our study. The GNAS gene encodes the
guanine nucleotide-binding protein G(s) subunit a respon-
sible for constitutively increased cAMP formation in the
mutant form. The detected p.R201H mutation has predom-
inantly been associated with neoplastic precursor lesions or
low-grade neoplastic lesions, such as ﬁbrous dysplasia,36
intraductal papillary mucinous neoplasm of the bile
duct,34,37 low-grade appendiceal mucinous neoplasias,38
and intestinal adenomas.39 Only 17% of Cosmic database
entries for GNAS mutations are from invasive cancers, with
only six conﬁrmed somatic mutations in invasive breast
cancer reported, again arguing for a low progression po-
tential to invasive breast cancer, as with AKT1 mutations
themselves. The second compound mutation (Case 3) dis-
played an MTOR mutation (p.V2406M) unequivocally
predicted as biologically relevant by algorithmic prediction
(SIFT score, 0.02). The mutation is localized at the kinase
domain of mTOR and was previously detected in anaplastic
astrocytoma40 and as a point mutation at identical position
with a different amino acid exchange (p.V2406A) in a
clear cell renal cell carcinoma.41 We thus regard this
mutation as an oncogenic driver mutation, which again
pertains to the PI3K/AKT/mTOR axis. Comparing the
recurrent detection of AKT1 compound mutations in our
study with the literature, no compound mutations were
found in UDH in the study by Troxell et al.31 The study
detected AKT1 mutations in 15% of papillomas with
UDH, but the study design would have precluded detec-
tion of AKT1 compound mutations because only AKT1
and PIK3CA wild-type tumors were further investigated
for an additional set of selected hot spot mutations not
comprising MTOR and GNAS.
The multigene panel used in our study also included
ESR1 encoding the estrogen receptor a. Fuqua et al12 have
reported ESR1 mutations in 34% of UDHs activating PI3K/
AKT signaling, which they showed to confer aromatase
inhibitor resistance in transfected MCF7 cells. In this regard,
no ESR1 mutations were detected in our samples. In addi-
tion, our study represents the ﬁrst comprehensive screen of
tumor-suppressor gene mutations in UDH, and no tumor-
suppressor gene mutations (eg, TP53, RB1, and PTEN)
were identiﬁed, indicating that tumor-suppressor gene
inactivation through mutation is not a feature in UDH.The American Journal of Pathology - ajp.amjpathol.orgImmunohistochemistry for components of the PI3K/
AKT/mTOR pathway displayed evidence for activation
downstream of mutated PI3K, AKT, and mTOR, respec-
tively, corroborating the biological relevance of the
respective mutations detected. We regard the results of the
phosphorylation-speciﬁc immunohistochemistry of PI3K/
AKT/mTOR pathway components as a valuable, overall
conﬁrmation that this pathway is functionally activated in
this type of lesion. Conversely, we would be reluctant to
question well-characterized oncogenic mutations known to
occur in the appropriate setting (breast), pathway (AKT
pathway), and context (proliferation) on the basis of
phosphorylation-speciﬁc immunohistochemistry alone. This
occurred because FFPE tissue might well show decreased
immunoreactivity for phosphorylation-speciﬁc antibodies,
possibly because of ﬁxation and/or tissue archiving condi-
tions. The fact that immunohistochemical positivity for
p-mTOR and p-S6 was also seen in some wild-type lesions
of our analysis may point to the possibility of yet uniden-
tiﬁed, alternative molecular driver alterations converging on
a common pathway downstream.
Regarding histomorphological characteristics, we evalu-
ated all lesions for the presence of focal apocrine metaplasia
(Table 1), commonly viewed as an indication of heteroge-
neous differentiation of UDH in papilloma. This feature has
been cited as a criterion in favor of a nonneoplastic nature of
the epithelial proliferation (traditionally equated with UDH)
in papilloma. Of 5 lesions, 4 (80%) with focal apocrine
metaplasia exhibited somatic mutations in our study,
arguing against such an interpretation and favoring focal
apocrine metaplasia as a histological feature possibly asso-
ciated with clonality/neoplasia.
In conclusion, our data demonstrate mutations in >60%
of investigated lesions (classic UDH and those arising in
papillomas combined). Assigning the pathogenic mutations
detected in our study to their respective pathways, all but
one (GNAS) are activating PI3K/AKT/mTOR signaling at
different levels, with PIK3CA and AKT1 most commonly
mutated. In addition, our study is the ﬁrst to demonstrate
functionally relevant mutations in PIK3R1, MTOR, and
GNAS in UDH. Speciﬁcally, oncogenic GNAS points to a
yet unrecognized role of altered G-protein signaling in a
subset of these lesions. With regard to the question whether
UDH is, in fact, an early, clonal neoplastic proliferation, the
authors certainly agree that the mere detection of a biolog-
ically relevant mutation is not proof of neoplasia without a
corresponding autonomous cell proliferate. It is known that
mutations in morphologically normal-appearing cells in the
vicinity of neoplastic alterations42 and even unassociated
with neoplasia have been demonstrated in various organs
and have been described in seemingly normal gastric mu-
cosa43 or chronic pancreatitis.44 On the contrary, UDH
displays clonality7 by loss of heterozygosity in a sizable
proportion of cases, is an intraductal mass-forming lesion at
the microscopic level and occasionally even macroscopi-
cally, and is not dissimilar in size and appearance to small21
Jahn et alpapillomas, which are universally accepted as benign
neoplastic alterations. In addition, papillomas and UDH
share the same speciﬁc AKT1 and PIK3CA mutations as
shown in our data and those of previous reports,13,31 and the
novel mutations detected in our study mostly map to the
same pathway (PI3K/AKT/mTOR) as well. In our opinion,
the triad of activating mutations, clonality, and the
morphological correlate of a mass forming lesion constitute
the rationale to regard and ﬁnally address UDH as a
neoplastic lesion (albeit with low risk of progression to
carcinoma) which according to our current knowledge, is
largely driven by mutational activation at different levels of
the PI3K/AKT/mTOR pathway.
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